H.C. Wainwright raised the firm’s price target on Connect Biopharma to $8 from $7 and keeps a Buy rating on the shares following the 2023 earnings report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTB:
- Connect Biopharma Triumphs with Rademikibart Trials
- Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
- Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference
- Connect Biopharma initiated with a Buy at H.C. Wainwright
